MarketPulse
K

$KYMR

4 articles found
3 positive
0 negative
1 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Kymera Therapeutics Advances IBD Pipeline With Promising KT-579 Preclinical Data

Kymera Therapeutics showcases KT-579 preclinical data matching approved IBD therapies ahead of Phase 1 trials in late 2026.
KYMRclinical trialinflammatory bowel disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kymera Therapeutics Lands $45M Milestone as FDA Fast-Tracks Asthma Drug

Kymera Therapeutics receives $45M from Gilead option exercise and FDA Fast Track designation for asthma drug KT-621, with Phase 2b data expected late 2027.
GILDKYMRasthmaGilead Sciences
The Motley FoolThe Motley Fool··Jonathan Ponciano

Major Hedge Fund Exits Protagonist Position Despite 120% Stock Surge

BVF Partners liquidated its $170M Protagonist stake despite 120% gains, likely due to changing risk profile as company awaits FDA decision on blood disorder treatment.
PTGXKYMRRVMDRVMDWclinical-stage biotechhedge fund liquidation
The Motley FoolThe Motley Fool··Jonathan Ponciano

BVF's $52M Stake in Disc Medicine Signals Confidence Despite Regulatory Hurdles

BVF Partners invests $52M in Disc Medicine despite FDA setbacks, betting on Phase 3 trial data and strong cash reserves through 2029.
KYMRRVMDRVMDWIRONFDA approvalclinical trial